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1Background and Purpose—White matter hyperintensities (WMH) of presumed vascular origin increase the risk of stroke 
and dementia. Despite strong WMH heritability, few gene associations have been identified. Relevant experimental 
models may be informative.
Methods—We tested the associations between genes that were differentially expressed in brains of young spontaneously 
hypertensive stroke–prone rats and human WMH (using volume and visual score) in 621 subjects from the Lothian Birth 
Cohort 1936 (LBC1936). We then attempted replication in 9361 subjects from the Cohorts for Heart and Aging Research 
in Genomic Epidemiology (CHARGE). We also tested the subjects from LBC1936 for previous genome-wide WMH 
associations found in subjects from CHARGE.
Results—Of 126 spontaneously hypertensive stroke–prone rat genes, 10 were nominally associated with WMH volume or 
score in subjects from LBC1936, of which 5 (AFP, ALB, GNAI1, RBM8a, and MRPL18) were associated with both WMH 
volume and score (P<0.05); 2 of the 10 (XPNPEP1, P=6.7×10−5; FARP1, P=0.024) plus another spontaneously hypertensive 
stroke–prone rat gene (USMG5, P=0.00014), on chromosomes 10, 13, and 10 respectively, were associated with WMH 
in subjects from CHARGE. Gene set enrichment showed significant associations for downregulated spontaneously 
hypertensive stroke–prone rat genes with WMH in humans. In subjects from LBC1936, we replicated CHARGE’s genome-
wide WMH associations on chromosomes 17 (TRIM65 and TRIM47) and, for the first time, 1 (PMF1).
Conclusions—Despite not passing multiple testing thresholds individually, these genes collectively are relevant to known 
WMH associations, proposed WMH mechanisms, or dementia: associations with Alzheimer's disease, late-life depression, 
ATP production, osmotic regulation, neurodevelopmental abnormalities, and cognitive impairment. If replicated 
further, they suggest a multifactorial nature for WMH and argue for more consideration of vascular contributions to 
dementia.   (Stroke. 2015;46:00-00. DOI: 10.1161/STROKEAHA.114.007649.)
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White matter hyperintensities (WMH) of presumed vas-cular origin, a major component of cerebral small ves-
sel disease (SVD), double the risk of stroke and dementia.1 
Despite considerable societal effect, the causes of WMH and 
SVD are poorly understood.2 Conventional vascular risk fac-
tors explain little of the WMH variance.3 Family studies,4 
several rare monogenic SVD disorders,5 and epidemiology6 
suggest that genetic predisposition is important.
Identification of genetic factors for SVD has been chal-
lenging. Several replicable single-nucleotide polymorphisms 
(SNPs) associated with WMH have been identified in 1 locus 
on chromosome 17q25,7,8 although the exact gene(s) and bio-
logical pathways to WMH are unclear. Few other replicable 
genes have been found in genome-wide association studies 
(GWAS),9,10 and little is known of their functional significance.
Experimental SVD models might provide insight into 
human SVD. The spontaneously hypertensive stroke–prone 
rat (SHRSP) is a relevant model of spontaneous SVD.11 It 
was selectively crossbred (1974) from Wistar-Kyoto (WKY) 
rats via the spontaneously hypertensive rat (SHR, 1963).12 
Hypertension, established in SHRSP rats by 10 weeks of 
age, is considered to be the main cause of their brain disease. 
However, differences in protein and gene expression in SHRSP 
rats versus WKY rats at 5 weeks of age (before measurable 
blood pressure rises) suggest underlying susceptibilities to 
SVD.13 Compared with WKY controls, 5-week-old SHRSP 
rats have reduced claudin 5 (tight junction) and myelin basic 
protein and increased microglia (IBA1) and glial activation 
(GFAP)13; at 16 and 21 weeks, increase in smooth muscle actin 
was seen, thought to reflect arteriolar smooth muscle hyperpla-
sia secondary to hypertension. SHRSP gene expression differ-
ences at 5 weeks of age were more numerous than at 16 or 21 
weeks of age and included downregulation of Mmp14, Mbp, 
GFAP, AVP, Alb, and Igf2, upregulation of Gucy1A3, Rps9, 
Fos, and JunB, early-growth response, cell-signaling genes, 
and overexpression of genes involved in neurological diseases 
(stroke, depression, and blood–brain barrier leakage),14 rather 
than just hypertension. Recent gene sequencing of SHRSP 
rats (and 26 other rat models of common human diseases)15 
revealed that genes that were either shared between or uniquely 
mutated in these rat models were significantly over-represented 
in human GWAS hits for hypertension or metabolism-related 
phenotypes, suggesting coevolution of these genes and their 
role in common diseases in models and humans.15
In a hypothesis-driven collaborative approach, we tested for 
associations between genes that were differentially expressed 
in the brains of 5-week-old SHRSP rats14 and WMH in 
humans. We used data from 5-week-old rats because gene 
expression differences were more frequent at that age than at 
16 or 21 weeks, and we wanted to minimize the confounding 
of tissue changes by secondary effects of hypertension and to 
optimize the chances of detecting genes related to WMH sus-
ceptibility. We focused on WMH as the most frequent feature 
of SVD with the most data available in replication cohorts. 
We first tested the subjects from Lothian Birth Cohort 1936 
(LBC1936)16,17 and then attempted replication in subjects 
from the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium.7 To provide confi-
dence in the relevance of subjects from LBC1936, we also 
sought CHARGE’s7 previously reported WMH-gene associa-
tions in the subjects from LBC1936.
Methods
Subjects
The subjects from LBC1936 are community-dwelling individuals 
living in South East Scotland who underwent detailed cognitive, bio-
medical, genetic assessments, and detailed brain MRI at ≈73 years of 
age (n=866).16,17 The MRI acquisition, methods for assessing WMH 
burden17 qualitatively18 and quantitatively,19 and proportions with 
WMH by either method20 have been reported. This study was ap-
proved by the Lothian (REC 07/MRE00/58) and Scottish Multicentre 
Table 1. Genes Associated With Cerebral Small Vessel Disease in Rats That Are Associated With WMH in Older Humans: 126 
Differentially Expressed Genes Between Spontaneously Hypertensive Stroke Prone and Wild-Type Rats Were Tested for Association 
With WMH in Subjects From LBC1936 and 10 Genes Were Significantly Associated (P<0.05) With Either WMH Volume or Fazekas Score 
Discovery: LBC1936 Replication: CHARGE






Chromosome Gene Start Position Stop Position nSNPs P Value P Value nSNPs P Value P Value nSNPs P Value
4 AFP 74 520 796 74 540 356 13 0.0021 0.00090 77 0.0037 0.0037 67 0.841
4 ALB 74 488 869 74 505 834 11 0.0026 0.0017 61 0.0063 0.0068 53 0.718
7 GNAI1 79 602 075 79 686 661 42 0.034 0.033 181 0.014 0.015 166 0.767
1 RBM8A 144 218 994 144 222 801 13 0.038 0.057 26 0.029 0.024 21 0.539
2 INPP5D 233 633 279 233 781 288 69 0.041 0.78 198 0.044 0.87 162 0.989
10 XPNPEP1 111 614 513 111 673 192 18 0.042 0.14 130 0.15 0.23 120 6.7×10–5
9 NR4A3 101 623 957 101 668 994 13 0.045 0.16 62 0.11 0.25 56 0.484
13 FARP1 97 593 434 97 900 024 154 0.049 0.25 550 0.18 0.51 468 0.024
6 MRPL18 160 131 481 160 139 451 24 0.059 0.039 89 0.16 0.048 76 0.224
1 SIPA1L2 230 600 334 230 717 866 80 0.087 0.0093 340 0.20 0.018 285 0.885
nSNPs is the number of SNPs considered in the gene test. CHARGE indicates Cohorts for Heart and Aging Research in Genomic Epidemiology; LBC1936, Lothian Birth 
Cohort 1936; SNP, single-nucleotide polymorphism; and WMH, white matter hyperintensities.
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(MREC/01/0/56) Research Ethics Committees; all subjects gave writ-
ten informed consent.
The subjects from LBC1936 had genome-wide SNP data on 
542 050 SNPs,21 imputed to 2.5 million SNPs with HapMap2.22 There 
were 621 participants (392 men) from LBC1936 with both MRI and 
genetic data (mean age, 72.67 years; SD=0.73 years; Table I and 
Methods in the online-only Data Supplement). We excluded 48 sub-
jects from LBC1936 with a history of stroke or dementia.
Gene Analysis
In the 5-week-old SHRSP rats, 162 genes were differentially ex-
pressed compared with 5-week-old WKY rats in frontal and midcor-
onal brain sections (Table II in the online-only Data Supplement).14 
We used the following databases to match the SHRSP Illumina IDs 
to human genes (Materials and Table II in the online-only Data 
Supplement): Ensembl—http://www.ensembl.org, GeneCards—
http://www.genecards.org, Illumina ID search—http://www.gen-
script.com, NCBI—http://www.ncbi.nlm.nih.gov, and Rat Genome 
Database—http://www.rgd.mcw.edu. Of the 162 SHRSP genes, 132 
had an equivalent human gene, 8 transcripts were mapped to the same 
gene, 20 were uncharacterized in humans, and 2 had no human ho-
mologue. Of the 132 genes, 126 were available for association testing 
using the Versatile Gene-based Association Study (VEGAS) test.23 
We first performed a genome-wide association analysis on subjects 
from LBC1936 using PLINK software24 to test the genetic associa-
tion between 542 050 genotyped SNPs and 2 WMH measurements 
using a linear regression analysis: (1) log transformed WMH volume 
(mL), with age, sex, intracranial volume, and first 4 multiple dimen-
sion scaling components for population stratification as covariates; 
and (2) summed Fazekas score of periventricular and deep WMH, 
with age, sex, and the first 4 multiple dimension scaling population 
stratification components as covariates. We used both WMH volume 
and Fazekas score20 to increase the reliability of the results. We did 
not stratify by vascular risk factors because hypertension (although 
it was the strongest vascular risk factor) explained <2% of WMH 
variance in subjects from LBC1936.3 The VEGAS software summa-
rized evidence for association with WMH in subjects from LBC1936 
per gene by considering the P values of all 543 050 SNPs that were 
located within 17 681 unique autosomal genes (including SNPs±50 
kb outside of genes to include regulatory regions). For a more direct 
comparison with CHARGE (which used imputed data), we also per-
formed a gene-based test on LBC1936’s 2 447 226 HapMap2 derived 
P values (after removing SNPs with a minor allele frequency of <0.01 
and imputation quality of <0.3) with VEGAS software as above.
Replication in Subjects From CHARGE
We then tested whether any of the 126 SHRSP genes were also as-
sociated with WMH in subjects from CHARGE by using data from 
CHARGE’s published genome-wide meta-analysis of WMH in 9361 
stroke-free individuals from 7 community-based cohorts.7 We per-
formed a gene-based test using VEGAS software, which summarized 
the evidence for association with WMH burden on a per gene basis, as 
above, by considering the associated P values of all HapMap2 SNPs 
located within 17 787 autosomal genes (including SNPs±50 kb out-
side of genes to include regulatory regions).
Gene Set Enrichment
We performed a gene set enrichment analysis25 to investigate the en-
richment of the 126 SHRSP genes in the LBC1936 and CHARGE 
data associated with WMH, accounting for whether these were upreg-
ulated or downregulated (online-only Data Supplement),26 corrected 
for multiple testing using a false discovery rate (FDR) method.27
Replication of Previous CHARGE Findings in 
Subjects From LBC1936
To demonstrate our ability to detect WMH-gene associations in 
subjects from LBC1936, we attempted replication of CHARGE’s 
genome-wide associations with WMH7,8 in the subjects from the 
LBC1936 Cohort in a genome-wide association analysis using the 
2 534 887 SNPs imputed to HapMap2, with WMH (volume and 
Fazekas score) in Mach2QTL software.28
We applied Bonferroni correction for multiple testing (P=0.05/126 
genes=0.0004). We did not include the 2 WMH phenotypes in the 
Bonferroni correction as they are highly correlated (r2=0.77). Because 
of the overconservative nature of Bonferroni correction for multiple 
testing,29 a nominal significance threshold of P value of <0.05 was 
required for replication efforts.
Results
SHRSP Genes in Subjects From LBC1936
Of the 126 candidate SHRSP-derived genes, 10 were nominally 
associated with WMH in subjects from LBC1936 (P<0.05; 
Table 1). Using imputed or genotyped data, 5 genes were 
associated with WMH volume (AFP, ALB, GNAI1 [RBM8A 
and INPP5D, both borderline]); 3 of these (AFP, ALB, and 
GNAI1) and 2 others (MRPL18 and SIPA1L2) were associated 
with WMH Fazekas scores. Three other genes were associated 
with WMH volume using genotyped data only (XNXPEP1, 
NR4A3, and FARP1). None of these genes individually passed 
Bonferroni correction in subjects from LBC1936 (all were 
P>0.0004), in part, reflecting the LBC1936 sample size.
SHRSP Genes in Subjects From CHARGE
Two of these 10 genes were also associated with WMH in 
subjects from CHARGE (XPNPEP1, P=6.7×10−5; and 
FARP1, P=0.024; Table 1). Full details of all 126 SHRSP to 
LBC1936 to CHARGE gene associations are given in Table 
III in the online-only Data Supplement. Several other of 
the 126 SHRSP genes (outside the 10/126 described above) 
showed significance at P<0.05 in subjects from CHARGE (eg, 
USMG5, MED17, ZNF461, C20orf7, EGR1, ARC, NUDT14, 
and MMP14) of which 1 (USMG5, P<0.000142) passed 
Bonferroni correction (P<0.0004).
Gene Set Enrichment
Using gene set enrichment analysis, all 126 SHRSP candidate 
genes were not enriched in subjects from LBC1936 for associa-
tion with WMH in the 17 681 genes tested here (WMH volume, 
P=0.34; Fazekas score, P=0.81), but this would not preclude the 
possibility that in either upregulated or downregulated gene sets, 
there was an abundance of genes showing an enriched associa-
tion. We tested the upregulated (n=76) and downregulated (n=50) 
SHRSP genes separately and found significant enrichment 
for Fazekas scores in SHRSP downregulated genes (P=0.035; 
FDR, 0.046) but not SHRSP upregulated genes (P=0.921; FDR, 
0.899). WMH volume showed significant enrichment in down-
regulated (P=0.018; FDR, 0.025) but not upregulated (P=0.802; 
FDR, 0.780) genes. In the CHARGE consortium, there was 
no significant enrichment for either the total set of 126 genes 
(P=0.0514), the upregulated (P=0.109; FDR, 0.266) or the 
downregulated genes (P=0.173; FDR, 0.149).
Replication of CHARGE’s Previous Genome-Wide 
Association in Subjects From LBC1936
We sought CHARGE’s previous genome-wide association 
results for WMH7 in subjects from LBC1936. Of CHARGE’s 
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15 SNPs (P<1×10−5) associated with WMH (Table 2),7 3 SNPs 
replicated in subjects from LBC1936 with both WMH vol-
ume and Fazekas score at P<0.05 (rs3744028, rs1055129, and 
rs1052053); rs1052053, a miss-sense variant on chromosome 
1 in the polyamine-modulated factor 1 gene (PMF1), has not 
replicated previously.
Discussion
We used a clinically relevant translational approach15 to iden-
tify potential new gene associations for WMH, a common 
cause of cognitive impairment, stroke, and dementia. We 
found parallels between differentially expressed genes in a 
young spontaneous SVD model and WMH-gene associations 
in older humans. Two novel genes on chromosome 10 derived 
from SHRSP rats were associated with WMH, XPNPEP1 in 
both LBC1936 and CHARGE and USMG5 in CHARGE only. 
Several other genes were nominally associated with WMH in 
LBC1936 or CHARGE although none passed multiple test-
ing. We replicated 3 of CHARGE’s WMH-gene associations 
in subjects from LBC1936: 2 (rs3744028 and rs1055129) 
on chromosome 17q25 and 1 previously unreplicated SNP 
(rs1052053) on chromosome 1, a miss-sense variant in the 
polyamine-modulated factor 1 gene, PMF1, that has a role 
in the cell cycle. Jointly, these approaches yielded 6 genes (3 
from the SHRSP rats and 3 replicates of a GWAS finding) 
and 5 further rat-derived genes based on the LBC1936 sample 
alone, which despite not passing multiple testing thresholds 
individually, as a group they are notable for their involvement 
in biological pathways relevant to WMH pathogenesis.2
Of the 2 SHRSP genes found in LBC1936 and CHARGE, 
XPNPEP1 is X-prolyl aminopeptidase (aminopeptidase P) 1, 
soluble, associated with biliary atresia, and located in a region 
on chromosome 10 that is associated with Alzheimer's dis-
ease.30 FARP1 is Pleckstrin domain protein 1, associated with 
brain volume differences,31 and important in synapse devel-
opment.32 The SHRSP-CHARGE–associated gene USMG5 is 
upregulated during skeletal muscle growth 5 homolog (also 
known as diabetes mellitus–associated protein in insulin sensi-
tive tissues, or DAPIT), sits on chromosome 10, and maintains 
ATP synthase populations in mitochondria.33 All 5 SHRSP 
genes associated with both WMH volume and Fazekas score 
in subjects from LBC1936 (AFP, ALB, GNAI1, RBM8A, and 
MRPL18) are associated with white matter–relevant diseases 
in humans. Despite not surviving correction for multiple test-
ing, there was a notable consistency in their association with 2 
separate WMH measures. AFP encodes α-fetoprotein, a major 
plasma protein produced in the yolk sac and liver during fetal 
life. Abnormally, high amounts of α-fetoprotein are found in 
ataxia telangiectasia,34 also associated with abnormal white 
matter.35 ALB encodes albumin, a soluble monomeric pro-
tein important for maintaining plasma oncotic pressure found 
in cerebral WMH,36 and cerebrospinal fluid as blood–brain 
barrier function deteriorates with ageing and dementia.2,37 
GNAI1 encodes guanine nucleotide–binding protein (G pro-
tein), alpha-inhibiting activity polypeptide 1, implicated with 
Alzheimer's disease.38 RBM8A is an RNA binding protein that 
has differential expression in Alzheimer's disease,39 associa-
tions with a range of intellectual disabilities in humans and 
anxiety-related behavior in mice,40 with schizophrenia, several 
neurodevelopmental intellectual disabilities, anxiety behavior 
and may target neuronal genes to regulate behaviors. WMH in 
old age are known associates of late-onset depression,41 and 
they are also associated with lower age 11 IQ.42 MRPL18 is the 
mitochondrial ribosomal protein L18, previously associated 
Table 2. Association of SNPs Previously Associated With WMH in CHARGE in Subjects From LBC1936 and the corresponding SNP 
Association Results Are Given for LBC1936 WMH Volume and Fazekas Score
CHARGE LBC1936 WMH Volume Fazekas Score
SNP Chromosome Nearest Gene Risk Allele Allele Freq P Value
Effect 
Allele Allele Freq r2 β P Value β P Value
rs3744028 17 TRIM65 C 0.18 4.0×10−9 T 0.81 0.99 −0.217 0.00287 −0.287 0.000511
rs1055129 17 TRIM47 G 0.30 4.1×10−8 G 0.28 0.97 0.286 9.5×10−6 0.305 3.34×10−5
rs7894407 10 PDCD11 T 0.63 6.1×10−7 T 0.63 0.99 −0.026 0.662 −0.029 0.665
rs1892525 1 RP11-518D3.1 G 0.69 7.2×10−7 G 0.73 0.99 0.070 0.269 0.107 0.135
rs10814323 9 RECK A 0.21 1.7×10−6 G 0.77 1.00 0.056 0.390 0.034 0.651
rs6992136 8 RPL32P19 G 0.85 3.2×10−6 G 0.85 0.81 0.101 0.259 0.075 0.458
rs11731436 4 AC097110.1 C 0.64 3.3×10−6 G 0.35 0.91 −0.035 0.565 −0.041 0.549
rs1052053 1 PMF1 A 0.62 5×10−6 G 0.39 1.00 −0.112 0.047 −0.127 0.048
rs2167089 3 AC098970.2 G 0.73 6×10−6 T 0.26 0.97 0.061 0.342 0.044 0.545
rs10012573 4 COL25A1 A 0.94 6×10−6 C 0.06 0.85 0.097 0.481 0.029 0.855
rs11625623 14 PTGDR G 0.23 7.7×10−6 G 0.23 1.00 −0.051 0.460 −0.021 0.792
rs16901064 5 RNASEN C 0.84 7.8×10−6 C 0.85 0.99 0.030 0.695 0.055 0.532
rs6945846 7 FOXP2 C 0.2 7.9×10−6 T 0.78 0.90 −0.036 0.625 0.113 0.175
rs11629135 14 MTHFD1 G 0.93 8.6×10−6 G 0.92 0.99 0.034 0.749 −0.057 0.641
rs9410016 9 C9orf62 G 0.41 9.7×10−6 G 0.39 0.99 −0.029 0.603 −0.041 0.521
Allele frequency is the frequency of the effect allele. r 2 is a measure of the imputation quality to HapMap2. β is the regression coefficient. CHARGE indicates 
Cohorts for Heart and Aging Research in Genomic Epidemiology; LBC1936, Lothian Birth Cohort 1936; SNP, single-nucleotide polymorphism; and WMH, white matter 
hyperintensities.
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with multiple sclerosis.43 These 7 SHRSP-derived genes are 
related to pathologies (ataxia telangiectasia, blood–brain 
barrier impairment, Alzheimer's disease, multiple sclerosis, 
depression, developmental intellectual disabilities, and brain 
size) that display white matter abnormalities or affect intellec-
tual function. Impaired ATP production because of defects in 
USMG5, the gene that replicated from SHRSP to CHARGE, 
could increase susceptibility to WMH via ischemia.
The genes that were downregulated in the SHRSP were 
significantly enriched in subjects from LBC1936 for WMH. 
This may be because, in a complex disease such as SVD/
WMH, several individually modest genetic defects in different 
components of key pathways, when present in combination, 
increase disease risk. This interpretation is consistent with dif-
ferential protein expression seen in SHRSP13 and the absence, 
so far, of individual major human gene defects explaining 
either sporadic WMH or lacunar stroke.9
The lack of consistent replication from SHRSP to LBC1936 
to CHARGE requires caution. The power and required sig-
nificance threshold of the LBC1936 was modest for GWAS, 
hence our hypothesis-driven approach. Genes associated with 
WMH in subjects from LBC1936 but not CHARGE could 
be false positives; other factors include greater heterogene-
ity of WMH assessment and greater age range in subjects 
from CHARGE. The narrow age range of subjects from 
LBC1936 minimizes the effect of age, possibly helping to 
expose relevant genes. CHARGE-contributing studies used 
several methods of quantifying WMH, different MR scanner 
field strengths, and generations of technology and sequences. 
However, WMH volume and visual scores are highly cor-
related,20 and our replication of 3 findings from CHARGE 
in subjects from LBC1936 suggests that our approach has 
some validity. The CHARGE cohorts may have used dif-
ferent imputation platforms or more SNPS may have failed 
quality assurance in subjects from LBC1936, contributing to 
differences between the imputation results. There are several 
limitations to gene-based analysis, including the omission of 
nonautosomal genes, the effect of noncausal SNPs to dilute 
association (in particular, in the presence of a strong genetic 
association with a single locus within or in the regulatory 
region of a given gene, thus missing important associations), 
the lack of knowledge on (and overlap of) gene boundar-
ies, the possibility that an SNP variant may influence a gene 
distal to its site, thus not corresponding to a gene that it is 
located next to it, and the potential of the genetic data not to 
tag causative genetic variants. Power may have been limited 
(despite CHARGE’s large sample size) to detect associations 
with some genes. We did not stratify the human cohorts by 
risk factors as these explained <2% of WMH variance in sub-
jects from LBC1936,3 and risk-stratified genetic data were 
unavailable for CHARGE. We did not test gene associations 
with other SVD features in addition to WMH because a total 
SVD burden score was not available for CHARGE. Although 
it is a relevant model of spontaneous SVD11,12 and of human 
hypertension and metabolic disorders,15 like any model, the 
SHRSP has translational limitations, arguing for additional 
studies at different ages and brain regions, with or without 
environmental stressors.
This work has the following strengths: accurate LBC1936 
WMH phenotyping17 and genetic information in this relatively 
large narrow age-range older population.16 The Glasgow SHRSP 
colony is long established, with carefully controlled environ-
ments. The mRNA data were obtained from the same rats that 
provided protein expression data.13 Replication in other SHRSP 
colonies and examination of related strains (eg, SHR’s) may 
be informative. The genomes of SHRSP and 26 other complex 
disease phenotype models were recently sequenced,15 showing 
associations between genes in rat models of hypertension and 
human GWAS hits for hypertension phenotypes.15 This pro-
vides support for our reverse-translational discovery approach, 
suggesting that genes in disease models have coevolved and 
may contribute to disease-related phenotypes in humans.
Our findings require validation. The selection of candidate 
genes for investigation could be widened by examining more 
genes from the 5-week-old SHRSP rats (Table II in the online-
only Data Supplement), other models,15 and in larger samples 
of well-phenotyped humans, such as from METASTROKE 
and the Wellcome Trust Case-Control Consortium. This trans-
lational analysis of experimental models and human disease 
suggests some aspects of the genetic architecture underlying 
SVD, stroke, and dementia and argues for greater awareness 
of vascular contributions to neurodegeneration.
Figure I and Tables IV and V in the online-only Data 
Supplement provide the top SNP (P<1×10−5) and gene 
(P<0.001) associations with WMH variables in subjects from 
LBC1936 for further reference.
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